Endocrine therapy in breast cancer patients during the longitudinal study of quality of life.docVIP

 PAGE \* MERGEFORMAT 14 Endocrine therapy in breast cancer patients during the longitudinal study of quality of life Breast cancer is one of the most common malignancy of women in a variety of malignant tumors of the body accounted for 7% to 10% [1], and the upward trend in the incidence, epidemiological survey shows that the incidence of breast cancer in some big cities have been living gynecological the first malignancy. In recent years, with surgery, radiotherapy, chemotherapy, endocrine therapy and other means of application of combined treatment of breast cancer patients with long-term survival have been significantly improved, especially for patients with hormone receptor-positive endocrine therapy is considered to be an adverse reaction small, high rate of patients with an important treatment benefit in quality of life ((quality of life, QOL more and more attention today, the treatment effect on patients quality of life is how it? This paper intends to make a study on this issue. 1 Subjects and methods 1.1 Objects August 2003 -2008 years in September, select the three tertiary hospital in Linyi city, the survey of patients diagnosed as breast cancer, chemotherapy after surgery or secondary, are being applied endocrine therapy, the patient voluntary investigation and ruled out mental illness History and illiteracy. 1.2 The sampling method is convenient, the use of questionnaires. By the researchers in these patients (hospital, outpatient review or follow-up period, questionnaires were distributed in three patients during the survey on: endocrine treatment (baseline survey 1, the application before endocrine therapy), endocrine therapy (oral or subcutaneous application of endocrine therapy application process, endocrine treatment (ie, disabled or endocrine therapy with endocrine therapy after 5 years or more for three surveys, 394 questionnaires were returned valid questionnaires (those who completed the survey 3) 203. 1.2.1 G